The latest drugs for Alzheimer's disease may add years of independence to the lives of patients, but possibly only for some.

Alzheimer’s disease doesn’t have a cure, meaning no treatment can reverse the damage that’s already occurred in the brain.

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and ...

The drug, gantenerumab, was abandoned by its developers, but subsequent anti-amyloid drugs lecanemab ( Leqembi) and donanemab ...

A new international study has offered hope that Alzheimer’s disease may one day be preventable—at least in people genetically ...

In Kenya, the Alzheimer’s and Dementia Organisation Kenya (ADOK) estimates that around 60,000 people are affected, a number ...

In a major Phase 3 clinical trial, lecanemab showed it could slow the decline in memory and thinking ability by 27% overall ...

Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain.

Scientists report long-term gantenerumab use might prevent cognitive decline in people with genetic predisposition to ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...